{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-021214","form_type":"8-K","ticker":"PSNL","cik":"0001527753","company_name":"Personalis, Inc.","filed_at":"2022-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.028219+00:00","generated_at":"2026-06-22T13:40:57.471805+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Personalis Q3 revenue $14.9M; core biopharma up 73% YoY; FY2022 guidance issued","bullets":["Q3 2022 revenue $14.9M vs $22.3M in Q3 2021; biopharma ex-VA revenue $14.9M (+73% YoY).","Net loss $26.5M ($0.58 EPS) vs net loss in prior year; cash $192.8M as of Sept 30, 2022.","FY2022 guidance: total revenue $63-64M, biopharma ex-VA $55.5-56.5M, net loss $111-114M.","Won exclusive 5-year VA MVP contract (subject to bidder protest); initial order received.","Appointed Christopher Hall as SVP, Diagnostic Business; launched NeXT Dx marketing and research collaborations with BC Cancer and Duke."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-021214","json":"https://secwatch.observer/filing/0000950170-22-021214.json","markdown":"https://secwatch.observer/filing/0000950170-22-021214.md","text":"https://secwatch.observer/filing/0000950170-22-021214.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1527753/000095017022021214/0000950170-22-021214-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1527753/000095017022021214/psnl-20221102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T13:40:57.471805+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a73ec7469332f27a3d62cf17daef5ec65a95847c","claim":"Personalis, Inc. reported the full year of 2022 results: revenue in the range of $63.0 million to $64.0 million, net income in the range of $111.0 million to $114.0 million. Guidance initiated.","evidence_excerpt":"Full Year 2022 Outlook Personalis expects the following for the full year of 2022: • Total company revenue is expected to be in the range of $63.0 million to $64.0 million • Revenue from biopharma and all other customers, excluding the VA MVP, is expected to be in the range of $55.5 million to $56.5 million • Net loss is expected to be in the range of $111.0 million to $114.0 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1527753/000095017022021214/0000950170-22-021214-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year of 2022"},{"label":"Revenue","value":"in the range of $63.0 million to $64.0 million"},{"label":"Net income","value":"in the range of $111.0 million to $114.0 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"e7e71597d5f095f4d8e82e8d51c6c4fbccf2066c","claim":"Personalis, Inc. reported the third quarter ended September 30, 2022 results: revenue $14.9 million, net income $26.5 million, EPS $0.58.","evidence_excerpt":"Revenue was $14.9 million in the three months ended September 30, 2022 • Gross margin was 16.7% in the three months ended September 30, 2022 • Operating expenses were $29.7 million in the three months ended September 30, 2022 • Net loss was $26.5 million in the three months ended September 30, 2022, and net loss per share was $0.58 based on a weighted-average basic and diluted share count of 45.9 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1527753/000095017022021214/0000950170-22-021214-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$14.9 million"},{"label":"Net income","value":"$26.5 million"},{"label":"EPS","value":"$0.58"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}